Report #2828321

Received Feb 26, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 66 yrs
State: CO
Recovered: Unknown
Vaccinated: Feb 17, 2025
Onset: Feb 17, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	3	93kk4	—

Symptoms (1)

Extra dose administered

Symptom narrative

administration of a 3rd dose of Shingrix; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 66-year-old female patient who received Herpes zoster (Shingrix) (batch number 93kk4, expiry date 31-JAN-2027) for prophylaxis. Previously administered products included Shingrix (1st dose received on 10th Oct 2024) and Shingrix (2nd dose received on 11th Dec 2024). On 17-FEB-2025, the patient received the 3rd dose of Shingrix. On 17-FEB-2025, an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: administration of a 3rd dose of Shingrix). The outcome of the extra dose administered was not applicable. Additional Information: GSK Receipt Date: 17-FEB-2025 The reporter called to request safety information as the immunocompetent patient received 3rd dose of Shingrix, which led to extra dose administered. The vaccine administration facility was the same as primary reporter.